Editas Medicine Inc (EDIT):企業の財務・戦略的SWOT分析

【英語タイトル】Editas Medicine Inc (EDIT) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(SWOT20MY0592)・商品コード:SWOT20MY0592
・発行会社(調査会社):GlobalData
・発行日:2019年12月
・ページ数:49
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Editas Medicine Inc (EDIT) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a clinical stage biotechnology company that develops genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of genetic and infectious diseases of eye, hematologic diseases, cancer, and diseases of muscle, lung and liver. The company works in collaboration with various biotechnology and pharmaceutical companies and research institutions. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.

Editas Medicine Inc Key Recent Developments

Nov 12,2019: Editas medicine announces third quarter 2019 results and update
Oct 28,2019: Editas Medicine appoints Judith R. Abrams, M.D., as Chief Medical Officer
Oct 15,2019: Editas Medicine and AskBio enter strategic research collaboration to explore in vivo delivery of genome editing medicines to treat neurological diseases
Aug 06,2019: Editas Medicine appoints Cynthia Collins as president and chief executive officer
Aug 06,2019: Editas Medicine announces second quarter 2019 results and update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Editas Medicine Inc – Key Facts
Editas Medicine Inc – Key Employees
Editas Medicine Inc – Key Employee Biographies
Editas Medicine Inc – Major Products and Services
Editas Medicine Inc – History
Editas Medicine Inc – Company Statement
Editas Medicine Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Editas Medicine Inc – Business Description
Editas Medicine Inc – Corporate Strategy
Editas Medicine Inc – SWOT Analysis
SWOT Analysis – Overview
Editas Medicine Inc – Strengths
Editas Medicine Inc – Weaknesses
Editas Medicine Inc – Opportunities
Editas Medicine Inc – Threats
Editas Medicine Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Editas Medicine Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 12, 2019: Editas medicine announces third quarter 2019 results and update
Oct 28, 2019: Editas Medicine appoints Judith R. Abrams, M.D., as Chief Medical Officer
Oct 15, 2019: Editas Medicine and AskBio enter strategic research collaboration to explore in vivo delivery of genome editing medicines to treat neurological diseases
Aug 06, 2019: Editas Medicine appoints Cynthia Collins as president and chief executive officer
Aug 06, 2019: Editas Medicine announces second quarter 2019 results and update
Apr 04, 2019: Editas and BlueRock partner to develop engineered cell medicines
Feb 28, 2019: Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update
Feb 19, 2019: Gamida Cell announces agreement with Editas Medicine to evaluate use of CRISPR genome editing technology in NAM-NK cells
Feb 06, 2019: Editas Medicine names David Scadden, M.D., to board of directors
Jan 22, 2019: Editas Medicine announces Chief Executive Officer Transition
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Editas Medicine Inc, Key Facts
Editas Medicine Inc, Key Employees
Editas Medicine Inc, Key Employee Biographies
Editas Medicine Inc, Major Products and Services
Editas Medicine Inc, History
Editas Medicine Inc, Subsidiaries
Editas Medicine Inc, Key Competitors
Editas Medicine Inc, Ratios based on current share price
Editas Medicine Inc, Annual Ratios
Editas Medicine Inc, Annual Ratios (Cont...1)
Editas Medicine Inc, Interim Ratios
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Editas Medicine Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Editas Medicine Inc, Performance Chart (2014 - 2018)
Editas Medicine Inc, Ratio Charts
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★調査レポート[Editas Medicine Inc (EDIT):企業の財務・戦略的SWOT分析] (コード:SWOT20MY0592)販売に関する免責事項を必ずご確認ください。
★調査レポート[Editas Medicine Inc (EDIT):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆